CLRB vs. CMPS, ACIU, CRBP, ALXO, TERN, ALT, SLRN, VERV, LXRX, and KRRO
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include COMPASS Pathways (CMPS), AC Immune (ACIU), Corbus Pharmaceuticals (CRBP), ALX Oncology (ALXO), Terns Pharmaceuticals (TERN), Altimmune (ALT), Acelyrin (SLRN), Verve Therapeutics (VERV), Lexicon Pharmaceuticals (LXRX), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical preparations" industry.
COMPASS Pathways (NASDAQ:CMPS) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
Cellectar Biosciences received 190 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 76.92% of users gave COMPASS Pathways an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
46.2% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 4.3% of COMPASS Pathways shares are owned by company insiders. Comparatively, 3.7% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
COMPASS Pathways presently has a consensus price target of $47.40, indicating a potential upside of 583.00%. Cellectar Biosciences has a consensus price target of $20.00, indicating a potential upside of 500.60%. Given Cellectar Biosciences' higher probable upside, research analysts plainly believe COMPASS Pathways is more favorable than Cellectar Biosciences.
COMPASS Pathways is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
COMPASS Pathways has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Cellectar Biosciences' return on equity of -57.24% beat COMPASS Pathways' return on equity.
In the previous week, COMPASS Pathways had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 2 mentions for COMPASS Pathways and 0 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.92 beat COMPASS Pathways' score of 0.00 indicating that COMPASS Pathways is being referred to more favorably in the media.
Summary
COMPASS Pathways beats Cellectar Biosciences on 11 of the 14 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
